Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1353098 | 1.00 | TSHR (0.40) | TSHRCASP1LMNAL3MBTL1GAA | |
| SCHEMBL30001058 | 0.76 | TSHR (0.41) | TSHRCASP1LMNAL3MBTL1GAA | |
| SCHEMBL7167365 | 0.75 | TSHR (0.43) | TSHRCASP1LMNA | |
| SCHEMBL7167366 | 0.75 | TSHR (0.43) | TSHRCASP1LMNA | |
| SCHEMBL25347852 | 0.74 | LMNA (0.35) | TSHRCASP1LMNAL3MBTL1GAA | |
| SCHEMBL8432322 | 0.73 | TSHR (0.48) | TSHRCASP1LMNAGAAALDH1A1 | |
| Cyclohexanone Oxime SCHEMBL9570768 | 0.71 | TSHR (0.52) | TSHRCASP1LMNAL3MBTL1GAA | |
| SCHEMBL25347856 | 0.71 | TSHR (0.32) | TSHRCASP1LMNAL3MBTL1 | |
| SCHEMBL11165836 | 0.71 | TSHR (0.36) | TSHRCASP1LMNA | |
| SCHEMBL11459056 | 0.71 | TSHR (0.36) | TSHRCASP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571881-A1 | PYRROLOPYRAZINE DERIVATIVES AS SYK AND JAK INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-03-27 | — | — | EP | disclosed |
| US-8329699-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | disclosed |
| WO-2011144584-A1 | PYRROLOPYRAZINE DERIVATIVES AS SYK AND JAK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-24 | — | — | WO | disclosed |
| US-20110288097-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288097-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, JAK2 | TSHR 1626/4885CASP1 690/4885LMNA 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.